$1495 | Single User
$2295 | Multi User
$4495 | Site License
$7495 | Global License

Global Multiple Myeloma Partnering 2012 to 2018
[Report Updated: 01-03-2018]

Published by Current Partnering: 01 Mar 2018 | 195816 | In Stock
Related Topics: Multiple Myeloma , Myeloma

Introduction

The Global Multiple Myeloma Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies.

• Trends in partnering deals

• Top deals by value

• Deals listed by company A-Z, industry sector, stage of development, technology type

The report provides understanding and access to the partnering deals and agreements entered into by the world’s leading healthcare companies.


The report provides an analysis of partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.


Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.


This data driven report contains multiple links to online copies of actual deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


The initial chapters of this report provide an orientation of partnering trends.


Chapter 1 provides an overview of the trends in partnering since 2012, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 2 provides a review of the top 10 most active companies in the therapy area, including a comprehensive listing of the deals announced by each company.


Chapter 3 provides a comprehensive directory of partnering deals signed and announced since 2012. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.


Chapter 4 provides a listing of partnering deals where a contract document is available alongside the deal record.


Chapters 5 and 6 provide a summary of M&A deals since 2012 where the acquired company is active in the therapy area of interest.

Chapters 7 and 8 provide a summary of financings since 2012 where the financed company is active in the therapy area of interest.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products in the therapy area.

Table of Contents
for Global Multiple Myeloma Partnering 2012 to 2018 [Report Updated: 01-03-2018]

  • Executive Summary

    Chapter 1 - Therapypartnering trends in numbers

    Partnering in numbers – by year

    Partnering in numbers – most active

    Partnering in numbers – by industry sector

    Partnering in numbers – by deal type

    Partnering in numbers – by technology type

    Partnering in numbers – by stage of development

    Chapter 2 - Most active dealmakers

    Chapter 3 - Partnering deals directory

    Partnering deals directory – by company A-Z

    Partnering deals directory – by deal value

    Partnering deals directory – by industry sector

    Partnering deals directory – by deal type

    Partnering deals directory – by stage of development

    Partnering deals directory – by technology area

    Chapter 4 - Partnering deals with a contract document

    Chapter 5 - SEARCH.THERAPY_AREA M&A in numbers

    M&A in numbers – by year

    Chapter 6 - M&A deals directory

    M&A deals directory – by company A-Z

    M&A deals directory – by deal value

    Chapter 7 - Financing in numbers

    Financing in numbers – by year

    Financing in numbers – by financing type

    Chapter 8 - Financing deals directory

    Financing deals directory – by company A-Z

    Financing deals directory – by deal value

    Financing deals directory – by financing type

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent titles from CurrentPartnering

    TABLE OF FIGURES

    Figure 1: Partnering frequency by year

    Figure 2: Partnering most active

    Figure 3: Partnering by industry sector

    Figure 4: Partnering by deal type

    Figure 5: Partnering by technology area

    Figure 6: Partnering by stage of development

    Figure 7: M&A frequency by year

    Figure 8: Financing frequency by year

    Figure 9: Financing by type

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

195816 | CP2201mul

Number of Pages

150

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Sanofi's Lemtrada finally approved in the US – how will neurologists use the multiple sclerosis therapy?
Scope Two years after it was first submitted for approval with the FDA, Sanofi's multiple sclerosis ...
25 Nov 2014 by FirstWord Pharma USD $695 More Info
KOL Insight: Multiple Sclerosis
IntroductionRecent launches of oral therapies have brought clinical advantages and clear patient ben...
06 Oct 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: How do neurologists value multiple sclerosis medical affairs teams – what could they be doing better?
Scope Medical affairs teams are playing an increasingly critical role for pharmaceutical manufacture...
18 Jun 2014 by FirstWord Pharma USD $695 More Info
Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?
Scope The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in par...
05 May 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Life-cycle management strategies in multiple sclerosis – can new versions of Copaxone, Avonex drive market share retention?
Scope With Copaxone and Avonex generating global sales of .3 billion and billion for Teva and B...
26 Mar 2014 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis: KOL Insight
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
01 Dec 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Multiple Sclerosis
IntroductionOver the next five years, the global multiple sclerosis (MS) market is set to grow from ...
01 Dec 2013 by FirstWord Pharma USD $4,995 More Info
Physician Views – Which multiple sclerosis players do the best marketing job? – FirstWord polls neurologists in the US and 5EU
ScopeThe multiple sclerosis market has undergone notable change over the past 2 years, primarily due...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Physician Views: Sanofi secures EU approval for its multiple sclerosis treatment Lemtrada – how will neurologists use it?
ScopeWith Sanofi securing European approval for its multiple sclerosis therapy Lemtrada last week, n...
01 Sep 2013 by FirstWord Pharma USD $695 More Info
Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules
IntroductionThe multiple sclerosis treatment landscape has undergone dramatic changes over the past ...
12 Mar 2013 by FirstWord Pharma USD $7,495 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Multiple Myeloma Partnering 2012 to 2018 [Report Updated: 01-03-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...